Feng Bi

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 791 citations

Oncology, Gastrointestinal Oncology, Cancer Management +8

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Feng‐Hua Wang, Xiao‐Tian Zhang, Yuanfang Li et al. · Cancer Communications · 2021 · 645 citations · Full text

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 383 citations · Full text

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Feng‐Hua Wang, Xiao‐Tian Zhang, Lei Tang et al. · Cancer Communications · 2023 · 328 citations · Full text

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study

Jianming Xu, Tae Won Kim, Lin Shen et al. · Journal of Clinical Oncology · 2017 · 247 citations

Cancer Management, Pharmacotherapy, Surgery +18